UV-A1 therapy for nephrogenic systemic fibrosis

Archives of Dermatology

Volumn 145, Issue 10, 2009, Pages 1170-1174

  Tran, Kien T ^a   Prather, Heidi B ^a   Cockerell, Clay J ^a   Jacobe, Heidi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; NEPHROGENIC SYSTEMIC FIBROSIS; PHOTOTHERAPY; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

AGED; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RADIATION DOSAGE; RECURRENCE; RENAL DIALYSIS; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 70350223981     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.245     Document Type: Article

References (48)

1. Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004; 50(8):2660-2666. (Pubitemid 39062729)
2. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35(4):238-249. (Pubitemid 43185214)
3. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114(7):563-572.
4. Cassis TB, Jackson JM, Sonnier GB, Callen JP. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol. 2006;45(1):56-59.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359-2362. (Pubitemid 44300951)
6. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007; 22(11):3174-3178. (Pubitemid 350202540)
7. Dundová I, Treska V, Simanek V, Michal M. Nephrogenic fibrosing dermopathy: a case study. Transplant Proc. 2005;37(10):4187-4190. (Pubitemid 43015986)
8. Schmook T, Budde K, Ulrich C, Neumayer HH, Fritsche L, Stockfleth E. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005;20(1): 220-222. (Pubitemid 40207632)
9. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148-157. (Pubitemid 46579705)
10. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial. 2008;21(2):129-134.
11. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785-790. (Pubitemid 38156308)
12. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep. 2006;8(2):151-157.
13. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54(2)(suppl):S31-S34. (Pubitemid 43113084)
14. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med. 2006;130(2):209-212. (Pubitemid 43237993)
15. Saenz A, Mandal R, Kradin R, Hedley-Whyte ET. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch. 2006;449(3):389-391. (Pubitemid 44367984)
16. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant. 2006;6(9):2212-2217. (Pubitemid 44199558)
17. Kay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003; 48(1):55-60. (Pubitemid 36091534)
18. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003;143(5):678-681. (Pubitemid 37452802)
19. Introcaso CE, Hivnor C, Cowper S, Werth VP. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol. 2007;46(5):447-452. (Pubitemid 46711420)
20. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245(1):168-175.
21. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007; 143(8):1025-1030. (Pubitemid 47296079)
22. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial. 2008;21(2):123-128.
23. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152(3):531-536. (Pubitemid 40547128)
24. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol. 2006;21(9):1307-1311.
25. Läuchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004; 208(3):278-280. (Pubitemid 38594553)
26. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543-2548.
27. Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol. 2003;148(3):563-568. (Pubitemid 36461338)
28. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139(7):903-906. (Pubitemid 36898926)
29. Lim HW, Honigsmann H, Hawk JLM. Photodermatology. New York, NY: Informa- Healthcare USA; 2007.
30. Dawe RS. Ultraviolet A1 phototherapy. Br J Dermatol. 2003;148(4):626-637.
31. Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140(11):1322-1324. (Pubitemid 39473630)
32. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979; 22(2):130-140. (Pubitemid 9156666)
33. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y. Antinuclear antibodies in localized scleroderma. Arthritis Rheum. 1983;26(5):612-616.
34. Scharffetter K, Wlaschek M, Hogg A, et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res. 1991; 283(8):506-511.
35. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol. 1992;99(4):440-444.
36. Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest. 2000;106(5):663-670. (Pubitemid 30691337)
37. McKenna KE, Whittaker S, Rhodes LE, et al; British Photodermatology Group; UK Skin Lymphoma Group. Evidence-based practice of photopheresis 1987- 2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol. 2006;154(1):7-20.
38. Dawe RS. Ultraviolet A1 phototherapy. Br J Dermatol. 2003;148(8):626-637.
39. Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140(11):1322-1324. (Pubitemid 39473630)
40. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35(4):238-249. (Pubitemid 43185214)
41. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979; 22(2):130-140. (Pubitemid 9156666)
42. Takehara K, Moroi Y, Nakabayashi Y, et al. Antinuclear antibodies in localized scleroderma. Arthritis Rheum. 1983;26(5):612-616.
43. Scharffetter K, Wlaschek M, Hogg A, et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res. 1991; 283(8):506-511.
44. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol. 1992;99(4):440-444.
45. Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest. 2000;106(5):663-670. (Pubitemid 30691337)
46. Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140(11):1322-1324. (Pubitemid 39473630)
47. Knopp EA. Cowper, SE Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial. 2008;21(2):123-128.
48. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol. 2006;154(1):7-20.